

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>New hematologic populations at risk of invasive... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1202/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1202" />
    
            <meta name="description" content="Read the original article in full on F1000Research: New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies" />
    
            <meta name="og:title" content="F1000Research Article: New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies.">
            <meta name="og:description" content="Read the latest article version by Corrado Girmenia, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="19501">
            <meta name="article-id" content="17836">
            <meta name="dc.title" content="New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies">
            <meta name="dc.description" content="The introduction of new targeted, biological, and cellular therapies in patients with hematologic malignancies has improved the outcomes of patients but in parallel has changed the frequency and epidemiology of infections, including invasive aspergillosis (IA). In this article, recent literature on the epidemiology and clinical findings of IA in patients who have lymphoproliferative and myeloproliferative diseases and are undergoing novel targeted treatment with kinase inhibitors, agents targeting cell surface antigens, chimeric antigen receptor-modified T cells, and antibodies to immune checkpoint molecules is reviewed and the clinical impact of IA on the overall management of the underlying disease is discussed. Overall, IA represents a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic malignancies) and the prolonged periods of therapy, a considerable number of unusual cases of Aspergillus infections can be expected in clinical practice.">
            <meta name="dc.subject" content="invasive aspergillosis, hematologic malignancies, targeted treatments">
            <meta name="dc.creator" content="Girmenia, Corrado">
            <meta name="dc.date" content="2019/07/26">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.17836.1">
            <meta name="dc.source" content="F1000Research 2019 8:1202">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="invasive aspergillosis">
            <meta name="prism.keyword" content="hematologic malignancies">
            <meta name="prism.keyword" content="targeted treatments">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/07/26">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1202">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.17836.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1202">
            <meta name="citation_title" content="New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies">
            <meta name="citation_abstract" content="The introduction of new targeted, biological, and cellular therapies in patients with hematologic malignancies has improved the outcomes of patients but in parallel has changed the frequency and epidemiology of infections, including invasive aspergillosis (IA). In this article, recent literature on the epidemiology and clinical findings of IA in patients who have lymphoproliferative and myeloproliferative diseases and are undergoing novel targeted treatment with kinase inhibitors, agents targeting cell surface antigens, chimeric antigen receptor-modified T cells, and antibodies to immune checkpoint molecules is reviewed and the clinical impact of IA on the overall management of the underlying disease is discussed. Overall, IA represents a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic malignancies) and the prolonged periods of therapy, a considerable number of unusual cases of Aspergillus infections can be expected in clinical practice.">
            <meta name="citation_description" content="The introduction of new targeted, biological, and cellular therapies in patients with hematologic malignancies has improved the outcomes of patients but in parallel has changed the frequency and epidemiology of infections, including invasive aspergillosis (IA). In this article, recent literature on the epidemiology and clinical findings of IA in patients who have lymphoproliferative and myeloproliferative diseases and are undergoing novel targeted treatment with kinase inhibitors, agents targeting cell surface antigens, chimeric antigen receptor-modified T cells, and antibodies to immune checkpoint molecules is reviewed and the clinical impact of IA on the overall management of the underlying disease is discussed. Overall, IA represents a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic malignancies) and the prolonged periods of therapy, a considerable number of unusual cases of Aspergillus infections can be expected in clinical practice.">
            <meta name="citation_keywords" content="invasive aspergillosis, hematologic malignancies, targeted treatments">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Corrado Girmenia">
            <meta name="citation_author_institution" content="Dipartimento di Ematologia, Oncologia, e Dermatologia, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy">
            <meta name="citation_publication_date" content="2019/07/26">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1202">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.17836.1">
            <meta name="citation_firstpage" content="1202">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1202/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1202.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=19501 /> <input type=hidden id=articleId name=articleId value=17836 /> <input type=hidden id=xmlUrl value="/articles/8-1202/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1202-v1.xml"> <input type=hidden id=article_uuid value=d7f2d693-3c39-476d-80ba-44b5a32ae7df /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.17836.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.17836.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1202"
  },
  "headline": "New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular...",
  "datePublished": "2019-07-26T15:32:54",
  "dateModified": "2019-07-26T15:32:54",
  "author": [
    {
      "@type": "Person",
      "name": "Corrado Girmenia"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The introduction of new targeted, biological, and cellular therapies in patients with hematologic malignancies has improved the outcomes of patients but in parallel has changed the frequency and epidemiology of infections, including invasive aspergillosis (IA). In this article, recent literature on the epidemiology and clinical findings of IA in patients who have lymphoproliferative and myeloproliferative diseases and are undergoing novel targeted treatment with kinase inhibitors, agents targeting cell surface antigens, chimeric antigen receptor-modified T cells, and antibodies to immune checkpoint molecules is reviewed and the clinical impact of IA on the overall management of the underlying disease is discussed. Overall, IA represents a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic malignancies) and the prolonged periods of therapy, a considerable number of unusual cases of Aspergillus infections can be expected in clinical practice."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1202.html",
            "name": "New hematologic populations at risk of invasive aspergillosis: focus..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> New hematologic populations at risk of invasive aspergillosis: focus... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=19501 data-id=17836 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17836.1" data-recommended="" data-doi="10.12688/f1000research.17836.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1202/v1/pdf?article_uuid=d7f2d693-3c39-476d-80ba-44b5a32ae7df" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-17836-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-17836-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-17836-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Girmenia C. New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1202 (<a class=new-orange href="https://doi.org/10.12688/f1000research.17836.1" target=_blank>https://doi.org/10.12688/f1000research.17836.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-17836-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=17836 id=track-article-signin-17836 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17836?target=/articles/8-1202.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19501 /> <input name=articleId type=hidden value=17836 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:girmenia@bce.uniroma1.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Corrado Girmenia</span></a><a href="https://orcid.org/0000-0002-3245-2357" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3245-2357</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:girmenia@bce.uniroma1.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Corrado Girmenia</span></a><a href="http://orcid.org/0000-0002-3245-2357" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3245-2357</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 26 Jul 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.17836.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Dipartimento di Ematologia, Oncologia, e Dermatologia, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy<br/> <p> <div class=margin-bottom> Corrado Girmenia <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53540-51679></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53542-51689></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=53543-51690></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The introduction of new targeted, biological, and cellular therapies in patients with hematologic malignancies has improved the outcomes of patients but in parallel has changed the frequency and epidemiology of infections, including invasive aspergillosis (IA). In this article, recent literature on the epidemiology and clinical findings of IA in patients who have lymphoproliferative and myeloproliferative diseases and are undergoing novel targeted treatment with kinase inhibitors, agents targeting cell surface antigens, chimeric antigen receptor-modified T cells, and antibodies to immune checkpoint molecules is reviewed and the clinical impact of IA on the overall management of the underlying disease is discussed. Overall, IA represents a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic malignancies) and the prolonged periods of therapy, a considerable number of unusual cases of <i>Aspergillus</i> infections can be expected in clinical practice. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> invasive aspergillosis, hematologic malignancies, targeted treatments </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Corrado Girmenia (<a href="mailto:girmenia@bce.uniroma1.it">girmenia@bce.uniroma1.it</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Corrado Girmenia </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Girmenia C. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Girmenia C. New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1202 (<a href="https://doi.org/10.12688/f1000research.17836.1" target=_blank>https://doi.org/10.12688/f1000research.17836.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 26 Jul 2019, <b>8</b>(F1000 Faculty Rev):1202 (<a href="https://doi.org/10.12688/f1000research.17836.1" target=_blank>https://doi.org/10.12688/f1000research.17836.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 26 Jul 2019, <b>8</b>(F1000 Faculty Rev):1202 (<a href="https://doi.org/10.12688/f1000research.17836.1" target=_blank>https://doi.org/10.12688/f1000research.17836.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e122>Introduction</h2><p class="" id=d13902e125>Invasive aspergillosis (IA) occurs infrequently among immunocompetent individuals but is a major infectious complication in immunocompromised patients, particularly those affected by hematologic malignancies, because of its high incidence and associated mortality<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>. Historically, acute leukemia (AL) and allogeneic hematopoietic stem cell transplant (allo-HSCT) represent the underlying conditions that put patientsat higher risk of IA, and most epidemiological studies and clinical trials of prophylaxis and therapy of IA involved these hematologic populations<sup><a href="#ref-4">4</a>–<a href="#ref-6">6</a></sup>. However, in recent decades, several studies have shown a change in the epidemiological patterns of IA with an increasing involvement of patients with other hematologic malignancies (OHMs) (that is, other than AL and allo-HSCT). Of 109 infections in a retrospective study of consecutive episodes of proven/probable invasive pulmonary aspergillosis diagnosed at an Italian hematologic center from 2006 to 2011, 51% were diagnosed in patients with AL, 20% in patients who underwent allo-HSCT, and 28% in those affected by lymphoproliferative diseases<sup><a href="#ref-7">7</a></sup>. Several national registries confirmed that OHMs represent frequent underlying conditions in patients with diagnosed IA<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a></sup>. According to the results of the Global Burden of Disease Study on cancer populations in 192 countries and territories, for each case of AL (acute myeloid leukemia and acute lymphoid leukemia), 5.3 cases of OHM (lymphoma, multiple myeloma, and chronic leukemias) were diagnosed in 2016<sup><a href="#ref-11">11</a></sup>. Nevertheless, although the overall incidence of IA in patients with OHM is less than 2%<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>, the number of cases of IA encountered in clinical practice in patients with OHM is highly relevant given the high number and prolonged survival of these patient populations.</p><p class="" id=d13902e165>Recent data show a different spectrum of infectious complications in patients with lymphoid and myeloid diseases treated with new targeted, biological, and cellular therapies with documented cases of invasive fungal diseases (IFDs) in certain populations<sup><a href="#ref-14">14</a>–<a href="#ref-19">19</a></sup>. However, most initial studies evaluating the efficacy and safety of novel treatments are performed in patients with a relapsed or refractory disease, making it difficult to establish the additional risk of infections conferred by novel agents and the effect of previous treatments, concurrent complex immunosuppression, and the role of the underlying disease.</p><p class="" id=d13902e175>In this article, recent literature on the epidemiology and clinical findings of IA in patients undergoing new targeted, biological, and cellular therapies is reviewed and the clinical impact of this complication on the overall management of the underlying disease is discussed.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e181>Bruton’s tyrosine kinase and phosphatidylinositol-3-kinase inhibitors</h2><p class="" id=d13902e184>Advances in the understanding of B-cell receptor (BCR) signaling and its role in promoting B-cell survival and proliferation have highlighted new targets for the treatment of chronic lymphocytic leukemia (CLL) and certain non-Hodgkin lymphomas (NHLs). Ibrutinib is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor that is indicated for use in adult patients with CLL, Waldenström’s macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma as single-agent therapy or in combination with other drugs (<a target=xrefwindow href="https://www.ema.europa.eu/documents/product-information/imbruvica-epar-product-information_en.pdf" id=d13902e186>https://www.ema.europa.eu/documents/product-information/imbruvica-epar-product-information_en.pdf</a>). Idelalisib is a first-in-class inhibitor of phosphatidylinositol-3-kinase delta (PIK3-delta), another component of the BCR signaling pathway, and is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of CLL in adult patients and as monotherapy for the treatment of follicular lymphoma in adult patients (<a target=xrefwindow href="https://www.ema.europa.eu/documents/product-information/zydelig-epar-product-information_en.pdf" id=d13902e189>https://www.ema.europa.eu/documents/product-information/zydelig-epar-product-information_en.pdf</a>).</p><p class="" id=d13902e193>Both ibrutinib and idelalisib affect critical components of the immune system, as proven by the increased infection burden reported in patients with hereditary mutations of both BTK and PIK3-delta<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. A key role for BTK in macrophage immune responses was demonstrated during experimental pulmonary aspergillosis indicating that ibrutinib blocks inflammatory responses to <i>A. fumigatus</i> in human macrophages through a BTK-dependent pathway<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. For these reasons, the risk of infection in patients with CLL and NHL treated with these new kinase inhibitors is higher than the overall risk reported in CLL and NHL populations<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>.</p><p class="" id=d13902e220>Evidence supporting the potential for infectious complications by the agents affecting the BCR has been provided mostly by clinical trials where infections (frequently of the respiratory tract) occurred typically at the beginning of treatment and the infection rate declined by more than half after a few months of therapy. However, specific epidemiological studies on infections treated with ibrutinib and idelalisib are scarce and most of the data derived from retrospective studies or from phase II or III clinical trials performed to test the efficacy and overall safety of these therapeutic agents but without detailed information on the infectious complications. An association with pulmonary IA was observed shortly after ibrutinib was licensed for use. Of 127 patients with relapsed or refractory CLL treated with ibrutinib with or without rituximab in a single-center study published in 2015, 33 (26%) discontinued treatment for different reasons. Overall, 14 of them discontinued ibrutinib because of adverse events or death, and in two cases a pulmonary IA was diagnosed<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d13902e227>Some real-life clinical series of patients who received ibrutinib as first-line or salvage therapy have recently been published along with detailed data on infectious complications. The spectrum of serious infections in 378 patients whose lymphoid malignancies were treated with ibrutinib from 2012 to 2016 at the Memorial Sloan Kettering Cancer Center was retrospectively reviewed<sup><a href="#ref-27">27</a></sup>. Overall, serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment, and IFDs were documented in 16 (37.2%). IFDs included proved or probable IA in eight patients and a concurrent probable IA and <i>Pneumocystis jirovecii</i> pneumonia in one patient. No patient was receiving an anti-fungal prophylactic regimen at the time of IA. The presence of neutropenia at any time during ibrutinib treatment and receipt of three or more previous anti-tumor regimens were significantly associated with an increased risk of severe infection. Specifically, the risk factor of corticosteroid use at any point during ibrutinib treatment was associated with the occurrence of IA. A single-institution retrospective study was carried out to find the type and incidence of opportunistic infections (OIs) during ibrutinib treatment and the characteristics and outcomes associated with risk<sup><a href="#ref-28">28</a></sup>. In 566 patients who received ibrutinib from June 2010 to March 2016 (74% of patients affected by CLL), the cumulative incidence of OI was 2.3% at 0.5 years and increased to 4.7% at 5 years. IFDs (mainly IA) accounted for 74% of OIs. In a multivariable analysis of at least three prior treatments (hazard ratio [HR] 2.87, 95% confidence interval [CI] 1.12–7.35; <i>P</i> = 0.028), diabetes (HR 3.63, 95% CI 1.50–8.77; <i>P</i> = 0.004) and liver disease (HR 7.53, 95% CI 2.14–26.49; <i>P</i> = 0.002) retained an independent association with OI development.</p><p class="" id=d13902e252>A multicenter survey aimed at identifying cases of IFD in patients whose CLL was treated with ibrutinib was conducted in France<sup><a href="#ref-29">29</a></sup>. Out of 33 IFDs, 27 were proven, probable, or possible IA with cerebral localization in 40% of cases. Remarkably, 85% of IFDs occurred in the first 6 months after starting ibrutinib and 61% occurred in the first 3 months. This trend suggests the possibility that the risk of IFDs, such as IA, decreases with longer exposure to ibrutinib. In the majority of cases, other factors such as corticosteroids, neutropenia, or combined immunochemotherapy that potentially contributed to decreased anti-fungal responses were present. The phenomenon of the high risk of cerebral localization of IA during ibrutinib therapy was also shown in a phase Ib study of ibrutinib treatment of primary central nervous system (CNS) lymphoma; that study reported a 39% incidence of IA in patients who concurrently received corticosteroids in the absence of neutropenia<sup><a href="#ref-30">30</a></sup>. To assess the role of BTK in the risk of <i>Aspergillus fumigatus</i> infections, the authors evaluated the outcome of IA by comparing the effect of an experimental <i>A. fumigatus</i> infection via pharyngeal aspiration in 26 BTK knockout and 20 wild-type mice. Overall, 27% of BTK knockout mice and no wild-type mice died after <i>A. fumigatus</i> infection, and more severe lung tissue damage and fungal burden were assessed by histology, indicating a contribution of BTK to the innate immune control of <i>Aspergillus</i> infection. These findings suggest that BTK inhibition by ibrutinib impairs innate fungal immune surveillance and that the unusually frequent involvement of the CNS by the fungal infection may be related to CNS macrophage inhibition by the kinase inhibitor. It should be noted that co-administration of dexamethasone or chemotherapy (or both) may exacerbate this effect.</p><p class="" id=d13902e276>For idelalisib, all studies reported a high rate (from 20 to 40%) of severe infectious complications, particularly during the first months of treatment, and pneumonia was the most frequent disease<sup><a href="#ref-31">31</a>–<a href="#ref-35">35</a></sup>. However, in these trials on patients with relapsed or refractory lymphoproliferative disease who received idelalisib, in contrast to trials on ibrutinib, IA was never reported. To the best of our knowledge, only anecdotal cases have been published<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>.</p><p class="" id=d13902e293>In conclusion, data from the available literature show that IA is a major infectious complication of ibrutinib treatment, particularly in patients with relapsed or refractory hematologic disease who receive corticosteroids. Although no benefit is expected from the universal use of anti-fungal prophylaxis, patients receiving ibrutinib should be closely monitored and IA should be considered when a pulmonary infiltrate or a cerebral lesion is documented<sup><a href="#ref-14">14</a></sup>. In any case, drug–drug interactions between azoles and ibrutinib limit widespread primary prophylaxis. Conversely, available data seem to show that idelalisib therapy does not increase the risk of IA regardless of other concurrent risk factors.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e303>Anti-apoptotic protein Bcl-2 inhibitors</h2><p class="" id=d13902e306>The elevated expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), encoded by the gene of BCL2, renders CLL cells and cells of other lymphoproliferative diseases resistant to apoptosis, resulting in the accumulation of long-lived clonal lymphocytes that characterize the disease. Venetoclax is a highly selective inhibitor of Bcl-2 and is indicated in the treatment of CLL patients who have received at least one prior therapy. Neutropenia was the most common grade 3 or 4 toxicity reported with venetoclax administration, but it was managed with either dose interruption or reduction, with or without granulocyte colony-stimulating factor, and the rate of febrile neutropenia was low<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. The rate of OIs did not appear to be higher with venetoclax compared with control arms. A comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL used an integrated dataset from three phase I/II studies: OI occurred in 11 patients (3.1%) and only two cases of pulmonary IA were documented<sup><a href="#ref-40">40</a></sup>. In conclusion, according to the published studies, IA does not seem to represent a significant complication in patients with CLL during treatment with venetoclax. Studies on the use of venetoclax in the treatment of NHL, multiple myeloma, and ALs are ongoing, and the available literature does not seem to show a significantly increased risk of infections, including IFD, in these populations<sup><a href="#ref-41">41</a>–<a href="#ref-44">44</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e330>Other kinase inhibitors</h2><p class="" id=d13902e333>Other kinase inhibitors (that is, BCR-ABL inhibitors and Janus kinase inhibitors) have been used for many years for the treatment of chronic myeloproliferative disorders with variable associated infectious complications. According to an extensive literature, these drugs do not expose patients to an increased risk of <i>Aspergillus</i> infections<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e349>Agents targeting lymphoid or myeloid cell surface antigens</h2><p class="" id=d13902e352>Over the last two decades, there has been increasing interest in developing monoclonal antibodies targeting different surface proteins on cells of lymphoid and myeloid lineages for the treatment of leukemia, lymphoma, and multiple myeloma. The safety profile of agents targeting the lymphoid and myeloid (CD19, CD20, CD52 CD22, CD30, CD33, and CD38) surface proteins were recently reviewed, and recommendations for infection prevention were suggested<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. Overall, the treatments were not associated with intrinsic increased risk of infection when compared with controls. In general, most adverse events, including infections, were related to the underlying hematologic malignancy phase and previous treatments. Although various OIs (herpetic infections and <i>P. jirovecii</i> pneumonia) may occur in patients who receive the above monoclonal antibodies and targeted agents, cases of IA have been only occasionally or never reported.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e369>Chimeric antigen receptor-modified T cells and antibodies to immune checkpoint molecule immunotherapy</h2><p class="" id=d13902e372>Immune modulation or “immunotherapy” is a promising therapeutic modality for a variety of cancers. Immunotherapy using targeted chimeric antigen receptor-modified T (CAR-T) cells or antibodies to immune checkpoint molecules represents a dramatic advance in cancer treatment and in particular in the treatment of certain hematologic malignancies. These therapies mediate immune-related adverse events which may mimic or increase the risk of several infections<sup><a href="#ref-45">45</a></sup>.</p><p class="" id=d13902e379>CAR-T cells use gene transfer technology (such as lentiviral or retroviral vectors) to re-program autologous or allogeneic T cells to express CARs, thereby re-directing their specificity to target specific tumor antigens<sup><a href="#ref-46">46</a></sup>. Once infused, T-cell products can expand and remain detectable for months to years<sup><a href="#ref-47">47</a>–<a href="#ref-49">49</a></sup>. Among hematologic malignancies, CD19-targeted CAR-T cells administered after lymphodepletion chemotherapy constitute a novel treatment for patients with refractory or relapsed B-cell malignancies, including acute lymphoblastic leukemia (ALL), CLL, and NHL. Tisagenlecleucel is the first CAR-T therapy approved for use in children and young adults with refractory or in a second or later relapse of B-ALL<sup><a href="#ref-47">47</a>,<a href="#ref-49">49</a></sup>. Tisagenlecleucel and axicabtagene ciloleucel have been used in the treatment of refractory large B-cell lymphoma with high rates of durable responses<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. Infectious risk after CAR-T cell therapy is related to the CAR-T toxicity but also to prior therapy. Although a first-line strategy is foreseeable, most of the efficacy and safety data of CAR-T cell treatments involve patients with relapsed or refractory disease at high infectious risk regardless of the salvage immune therapy. A common and challenging complication of CAR-T therapies is the cytokine release syndrome (CRS), which is often characterized by high fever, hypoxia, hypotension, acute kidney injury, transaminitis, and multiorgan dysfunction. Most infections following CAR-T therapy occur during neutropenia or following severe CRS or both<sup><a href="#ref-45">45</a>,<a href="#ref-52">52</a></sup>. Infections generally occur within the first 10 days after CAR-T infusion and, when associated with CRS, may be severe and poorly responsive to antimicrobial therapy.</p><p class="" id=d13902e414>Infections occurring between days 0 and 90 in 133 patients with ALL, CLL, and NHL treated with CD19 CAR-T cells in a phase 1/2 study at the Fred Hutchinson Cancer Research Center were reviewed<sup><a href="#ref-53">53</a></sup>. There were 43 infections in 30 (23%) of 133 patients within 28 days after CAR–T cell infusion. Between 29 and 90 days after CAR–T cell infusion, 23 infections occurred in 17 (14%) of 119 evaluable patients. Overall, eight IFDs occurred in six patients (3%), all of whom had severe CRS or neurotoxicity requiring specific treatment and five of whom were autologous or allogeneic HSCT recipients. In three cases, a mold infection was documented: one patient developed a severe <i>A. fumigatus</i> sinusitis and an acute pulmonary hemorrhage due to invasive <i>Aspergillus ustus,</i> and tracheobronchitis was the primary cause of death in another patient with CLL without neutropenia who died 90 days after CAR–T cell infusion. Infections occurring within the first 6 months in 53 adult patients with relapsed or refractory B-ALL treated with CD19-targeted CAR T cells in a phase I clinical trial at Memorial Sloan Kettering Cancer Center were retrospectively reviewed<sup><a href="#ref-52">52</a></sup>. A mold-active anti-fungal prophylaxis (micafungin, posaconazole, and voriconazole) was administered in 41 (77%) of 53 patients. Overall, 22 (42%) of 53 patients experienced 26 infections within the first 30 days of CAR–T cell infusion and 10 (31%) of 32 patients who attained complete remission developed an infection later. Most of the infections were of bacterial origin, and a probable pulmonary IA was documented in three patients (5.7%) while under micafungin prophylaxis. A CRS grade of at least 3 was predictive of infection, but no specific analysis was performed for the risk of IA.</p><p class="" id=d13902e431>Biological evidence has shown the crucial role of the host immune system in the control of cancer. This led to the creation of monoclonal antibodies that target immune checkpoint signaling pathways and enhance T-cell cytotoxic activity, thereby inducing tumor cell lysis. Cell surface “immune checkpoint receptors”, which usually prevent excessive or non-specific activation of T cells such as programmed cell death receptor 1 (PD-1) or PD-1 ligand (PD-1L) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are targeted by immune checkpoint inhibitors (ICIs). Among the ICIs, PD-1/PD-1L and CTLA-4 inhibitors showed promising therapeutic outcomes, and some have been approved for certain cancer treatments and others are under clinical trials<sup><a href="#ref-54">54</a></sup>.</p><p class="" id=d13902e439>Antibodies targeting PD-1 and CTLA-4 have been investigated in lymphoid malignancies with varying levels of activity and a favorable toxicity profile<sup><a href="#ref-55">55</a>–<a href="#ref-57">57</a></sup>. To date, anti–PD-1 antibodies such as nivolumab and pembrolizumab have been evaluated in the setting of relapsed or refractory disease with encouraging response rates, particularly in classic Hodgkin lymphoma but also in follicular lymphoma and diffuse large B-cell lymphoma<sup><a href="#ref-55">55</a>–<a href="#ref-57">57</a></sup>.</p><p class="" id=d13902e456>The adverse events of ICI therapies are related to T-cell cytotoxicity with consequent tumor lysis, fever, and cell damage. Upregulated immune function may target normal tissues expressing immune checkpoint receptors with a consequent release of inflammatory cytokines, antibody binding, and complement activation on normal cells. Other manifestations may be systemic or organ-specific and possibly life-threatening inflammatory reactions. Toxicities may manifest weeks to months after initial treatment but are generally unusual after 3 months<sup><a href="#ref-45">45</a></sup>. Infections are a possible complication of ICI therapies, but distinguishing between infections and inflammatory-related manifestations is a challenge. Furthermore, ICIs may enhance inflammation because of infection with a manifestation similar to that of immune reconstitution inflammatory syndrome (IRIS), and anti-inflammatory treatments for inflammatory-related adverse events may mask clinical findings of infection. The treatment of inflammatory reaction, which usually includes steroids, may favor the development of <i>P. jirovecii</i> pneumonia and herpesvirus infection, and screening for tuberculosis, endemic fungi, and viral hepatitis B and C is required prior to these treatments<sup><a href="#ref-18">18</a>,<a href="#ref-54">54</a>–<a href="#ref-57">57</a></sup>. According to the results of the published clinical trials, ICI therapy in patients with hematologic malignancies does not increase the risk of major opportunistic fungal infections, including IA, beyond the impacts of underlying malignancy and chemotherapy. However, the well-known difficulties in the diagnosis make the data on the real incidence of IA probably unreliable. A peculiar biological effect of checkpoint inhibitors is represented by the possible increase of the host immune response against infections, including those caused by fungi. Preclinical evidence and an anecdotal description of anti–PD-1 activity against fungal sepsis in humans have been reported<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>. Checkpoint inhibitors could attenuate the clinical progression of invasive aspergillosis and synergize with anti-fungal therapy<sup><a href="#ref-60">60</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13902e490>Conclusions and perspectives</h2><p class="" id=d13902e493>The recent introduction of new targeted, biological, and cellular therapies has dramatically changed the outcome and complications of several hematologic malignancies. Infections continue to represent challenging adverse events of these therapeutic options but with clinical and epidemiological findings significantly different from those observed in AL patients undergoing intensive chemotherapy and HSCT recipients. Overall, IFDs, including IA, represent a variable and uncommon complication in these populations, but given the increasing eligibility criteria of these novel treatments (particularly in patients with relapsed or refractory hematologic disease) and the prolonged periods of therapy, a considerable number of unusual cases of <i>Aspergillus</i> infections can be expected in clinical practice. Given the variable and prolonged period of infectious risk, mold-active prophylaxis is not recommended, but it seems crucial to maintain a high level of diagnostic suspicion with the awareness that IA is a possible complication, particularly during certain treatments. In the event of anti-fungal prophylaxis or therapy, the phenomenon of drug–drug interactions should be considered when certain drugs are co-administered with triazoles. These anti-fungals are inhibitors of the cytochrome enzymes (in particular, CYP3A4), which modulate the metabolism of certain kinase inhibitors such as ibrutinib, and venetoclax. Decisions on the co-administration of these molecules and on the modulation of the dosages are challenging issues in clinical practice. A limit of the data in the available literature is represented by the fact that most information on IA in populations with OHM (that is, other than AL an HSCT) derives from clinical trials not designed for infection purposes. Furthermore, a large part of this population is represented by outpatients receiving oral therapy for prolonged periods outside the control of treating physicians; this makes adequate epidemiological surveillance even more complex. As a consequence, it is difficult to define infection control measures tailored to the emerging hematologic populations undergoing new targeted treatment strategies. It is therefore necessary to carry out continuous surveillance programs of the infectious complications in order to detect in real time any change in the epidemiology of IA and to establish appropriate and tailored diagnostic and preventive approaches.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d13902e1 class=n-a></a><h2 class=main-title id=d14098>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d13902e503 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d14300>References</h2><div class="section ref-list"><a name=d13902e503 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d13902e510 class=n-a></a>Gregg KS, Kauffman CA: Invasive Aspergillosis: Epidemiology, Clinical Aspects, and Treatment. <i>Semin Respir Crit Care Med.</i> 2015; <b>36</b>(5): 662–72. <a target=xrefwindow id=d13902e518 href="http://www.ncbi.nlm.nih.gov/pubmed/26398533">PubMed Abstract </a> | <a target=xrefwindow id=d13902e521 href="https://doi.org/10.1055/s-0035-1562893">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d13902e530 class=n-a></a>Zilberberg MD, Nathanson BH, Harrington R, <i> et al.</i>: Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013. <i>Clin Infect Dis.</i> 2018; <b>67</b>(5): 727–35. <a target=xrefwindow id=d13902e541 href="http://www.ncbi.nlm.nih.gov/pubmed/29718296">PubMed Abstract </a> | <a target=xrefwindow id=d13902e544 href="https://doi.org/10.1093/cid/ciy181">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733175739"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e553 class=n-a></a>van de Peppel RJ, Visser LG, Dekkers OM, <i> et al.</i>: The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review. <i>J Infect.</i> 2018; <b>76</b>(5): 550–62. <a target=xrefwindow id=d13902e564 href="http://www.ncbi.nlm.nih.gov/pubmed/29727605">PubMed Abstract </a> | <a target=xrefwindow id=d13902e567 href="https://doi.org/10.1016/j.jinf.2018.02.012">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733175739">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d13902e580 class=n-a></a>Pagano L, Busca A, Candoni A, <i> et al.</i>: Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Rev.</i> 2017; <b>31</b>(2): 17–29. <a target=xrefwindow id=d13902e591 href="http://www.ncbi.nlm.nih.gov/pubmed/27682882">PubMed Abstract </a> | <a target=xrefwindow id=d13902e594 href="https://doi.org/10.1016/j.blre.2016.09.002">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d13902e603 class=n-a></a>Pagano L, Caira M, Candoni A, <i> et al.</i>: Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica.</i> 2010; <b>95</b>(4): 644–50. <a target=xrefwindow id=d13902e614 href="http://www.ncbi.nlm.nih.gov/pubmed/19850903">PubMed Abstract </a> | <a target=xrefwindow id=d13902e617 href="https://doi.org/10.3324/haematol.2009.012054">Publisher Full Text </a> | <a target=xrefwindow id=d13902e621 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2857195">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d13902e631 class=n-a></a>Girmenia C, Raiola AM, Piciocchi A, <i> et al.</i>: Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biol Blood Marrow Transplant.</i> 2014; <b>20</b>(6): 872–80. <a target=xrefwindow id=d13902e642 href="http://www.ncbi.nlm.nih.gov/pubmed/24631738">PubMed Abstract </a> | <a target=xrefwindow id=d13902e645 href="https://doi.org/10.1016/j.bbmt.2014.03.004">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d13902e654 class=n-a></a>Girmenia C, Guerrisi P, Frustaci AM, <i> et al.</i>: New category of probable invasive pulmonary aspergillosis in haematological patients. <i>Clin Microbiol Infect.</i> 2012; <b>18</b>(10): 990–6. <a target=xrefwindow id=d13902e665 href="http://www.ncbi.nlm.nih.gov/pubmed/21999366">PubMed Abstract </a> | <a target=xrefwindow id=d13902e668 href="https://doi.org/10.1111/j.1469-0691.2011.03685.x">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d13902e677 class=n-a></a>Perkhofer S, Lass-Flörl C, Hell M, <i> et al.</i>: The Nationwide Austrian <i>Aspergillus</i> Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. <i>Int J Antimicrob Agents.</i> 2010; <b>36</b>(6): 531–6. <a target=xrefwindow id=d13902e691 href="http://www.ncbi.nlm.nih.gov/pubmed/20947312">PubMed Abstract </a> | <a target=xrefwindow id=d13902e695 href="https://doi.org/10.1016/j.ijantimicag.2010.08.010">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11803956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e704 class=n-a></a>Lortholary O, Gangneux JP, Sitbon K, <i> et al.</i>: Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). <i>Clin Microbiol Infect.</i> 2011; <b>17</b>(12): 1882–9. <a target=xrefwindow id=d13902e715 href="http://www.ncbi.nlm.nih.gov/pubmed/21668573">PubMed Abstract </a> | <a target=xrefwindow id=d13902e718 href="https://doi.org/10.1111/j.1469-0691.2011.03548.x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11803956">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d13902e731 class=n-a></a>Montagna MT, Lovero G, Coretti C, <i> et al.</i>: SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. <i>Infection.</i> 2014; <b>42</b>(1): 141–51. <a target=xrefwindow id=d13902e742 href="http://www.ncbi.nlm.nih.gov/pubmed/24150958">PubMed Abstract </a> | <a target=xrefwindow id=d13902e745 href="https://doi.org/10.1007/s15010-013-0539-3">Publisher Full Text </a> | <a target=xrefwindow id=d13902e749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3906525">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d13902e758 class=n-a></a>Fitzmaurice C: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study. <i>JCO.</i> 2018; <b>36</b>: 1568. <a target=xrefwindow id=d13902e766 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.1568">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718149482"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e776 class=n-a></a>Nosari AM, Pioltelli ML, Riva M, <i> et al.</i>: Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience. <i>Leuk Lymphoma.</i> 2014; <b>55</b>(8): 1844–8. <a target=xrefwindow id=d13902e787 href="http://www.ncbi.nlm.nih.gov/pubmed/24138328">PubMed Abstract </a> | <a target=xrefwindow id=d13902e790 href="https://doi.org/10.3109/10428194.2013.853299">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718149482">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733770214"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e803 class=n-a></a>Maertens JA, Girmenia C, Brüggemann RJ, <i> et al.</i>: European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>J Antimicrob Chemother.</i> 2018; <b>73</b>(12): 3221–3230. <a target=xrefwindow id=d13902e814 href="http://www.ncbi.nlm.nih.gov/pubmed/30085172">PubMed Abstract </a> | <a target=xrefwindow id=d13902e817 href="https://doi.org/10.1093/jac/dky286">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733770214">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d13902e830 class=n-a></a>Reinwald M, Silva JT, Mueller NJ, <i> et al.</i>: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). <i>Clin Microbiol Infect.</i> 2018; <b>24 Suppl 2</b>: S53–S70. <a target=xrefwindow id=d13902e841 href="http://www.ncbi.nlm.nih.gov/pubmed/29454849">PubMed Abstract </a> | <a target=xrefwindow id=d13902e844 href="https://doi.org/10.1016/j.cmi.2018.02.009">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d13902e853 class=n-a></a>Drgona L, Gudiol C, Lanini S, <i> et al.</i>: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). <i>Clin Microbiol Infect.</i> 2018; <b>24 Suppl 2</b>: S83–S94. <a target=xrefwindow id=d13902e864 href="http://www.ncbi.nlm.nih.gov/pubmed/29572070">PubMed Abstract </a> | <a target=xrefwindow id=d13902e867 href="https://doi.org/10.1016/j.cmi.2018.03.022">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d13902e876 class=n-a></a>Mikulska M, Lanini S, Gudiol C, <i> et al.</i>: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). <i>Clin Microbiol Infect.</i> 2018; <b>24 Suppl 2</b>: S71–S82. <a target=xrefwindow id=d13902e887 href="http://www.ncbi.nlm.nih.gov/pubmed/29447988">PubMed Abstract </a> | <a target=xrefwindow id=d13902e890 href="https://doi.org/10.1016/j.cmi.2018.02.003">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d13902e899 class=n-a></a>Winthrop KL, Mariette X, Silva JT, <i> et al.</i>: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). <i>Clin Microbiol Infect.</i> 2018; <b>24 Suppl 2</b>: S21–S40. <a target=xrefwindow id=d13902e910 href="http://www.ncbi.nlm.nih.gov/pubmed/29447987">PubMed Abstract </a> | <a target=xrefwindow id=d13902e913 href="https://doi.org/10.1016/j.cmi.2018.02.002">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d13902e923 class=n-a></a>Redelman-Sidi G, Michielin O, Cervera C, <i> et al.</i>: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). <i>Clin Microbiol Infect.</i> 2018; <b>24 Suppl 2</b>: S95–S107. <a target=xrefwindow id=d13902e934 href="http://www.ncbi.nlm.nih.gov/pubmed/29427804">PubMed Abstract </a> | <a target=xrefwindow id=d13902e937 href="https://doi.org/10.1016/j.cmi.2018.01.030">Publisher Full Text </a> | <a target=xrefwindow id=d13902e941 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5971148">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d13902e950 class=n-a></a>Kansagra AJ, Frey NV, Bar M, <i> et al.</i>: Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplant.</i> 2019; <b>379</b>: 64. <a target=xrefwindow id=d13902e961 href="https://doi.org/10.1038/s41409-019-0451-2">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d13902e970 class=n-a></a>Winkelstein JA, Marino MC, Lederman HM, <i> et al.</i>: X-linked agammaglobulinemia: report on a United States registry of 201 patients. <i>Medicine (Baltimore).</i> 2006; <b>85</b>(4): 193–202. <a target=xrefwindow id=d13902e981 href="http://www.ncbi.nlm.nih.gov/pubmed/16862044">PubMed Abstract </a> | <a target=xrefwindow id=d13902e984 href="https://doi.org/10.1097/01.md.0000229482.27398.ad">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d13902e993 class=n-a></a>Xie S, Chen M, Yan B, <i> et al.</i>: Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. <i>PLoS One.</i> 2014; <b>9</b>(4): e94496. <a target=xrefwindow id=d13902e1004 href="http://www.ncbi.nlm.nih.gov/pubmed/24718556">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1007 href="https://doi.org/10.1371/journal.pone.0094496">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3981814">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d13902e1020 class=n-a></a>Herbst S, Shah A, Mazon Moya M, <i> et al.</i>: Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to <i>Aspergillus fumigatus</i>. <i>EMBO Mol Med.</i> 2015; <b>7</b>(3): 240–58. <a target=xrefwindow id=d13902e1034 href="http://www.ncbi.nlm.nih.gov/pubmed/25637383">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1038 href="https://doi.org/10.15252/emmm.201404556">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4364943">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733679195"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1050 class=n-a></a>Bercusson A, Colley T, Shah A, <i> et al.</i>: Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during <i>Aspergillus fumigatus</i> phagocytosis. <i>Blood.</i> 2018; <b>132</b>(18): 1985–8. <a target=xrefwindow id=d13902e1064 href="http://www.ncbi.nlm.nih.gov/pubmed/30021784">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1068 href="https://doi.org/10.1182/blood-2017-12-823393">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6450054">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733679195">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727806126"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1085 class=n-a></a>Williams AM, Baran AM, Meacham PJ, <i> et al.</i>: Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. <i>Leuk Lymphoma.</i> 2018; <b>59</b>(3): 625–32. <a target=xrefwindow id=d13902e1096 href="http://www.ncbi.nlm.nih.gov/pubmed/28696801">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1099 href="https://doi.org/10.1080/10428194.2017.1347931">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727806126">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d13902e1112 class=n-a></a>Reinwald M, Boch T, Hofmann WK, <i> et al.</i>: Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. <i>Biomark Insights.</i> 2016; <b>10</b>(Suppl 3): 55–68. <a target=xrefwindow id=d13902e1123 href="http://www.ncbi.nlm.nih.gov/pubmed/27127405">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1126 href="https://doi.org/10.4137/BMI.S22430">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1130 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4841329">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d13902e1139 class=n-a></a>Jain P, Keating M, Wierda W, <i> et al.</i>: Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood.</i> 2015; <b>125</b>(13): 2062–7. <a target=xrefwindow id=d13902e1150 href="http://www.ncbi.nlm.nih.gov/pubmed/25573991">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1153 href="https://doi.org/10.1182/blood-2014-09-603670">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1157 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4467871">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732806284"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1166 class=n-a></a>Varughese T, Taur Y, Cohen N, <i> et al.</i>: Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. <i>Clin Infect Dis.</i> 2018; <b>67</b>(5): 687–92. <a target=xrefwindow id=d13902e1177 href="http://www.ncbi.nlm.nih.gov/pubmed/29509845">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1180 href="https://doi.org/10.1093/cid/ciy175">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6093991">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732806284">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735835420"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1197 class=n-a></a>Rogers KA, Mousa L, Zhao Q, <i> et al.</i>: Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia.</i> 2019. <a target=xrefwindow id=d13902e1205 href="http://www.ncbi.nlm.nih.gov/pubmed/31086260">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1208 href="https://doi.org/10.1038/s41375-019-0481-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735835420">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732656056"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1221 class=n-a></a>Ghez D, Calleja A, Protin C, <i> et al.</i>: Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. <i>Blood.</i> 2018; <b>131</b>(17): 1955–9. <a target=xrefwindow id=d13902e1232 href="http://www.ncbi.nlm.nih.gov/pubmed/29437588">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1235 href="https://doi.org/10.1182/blood-2017-11-818286">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732656056">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727663539"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1249 class=n-a></a>Lionakis MS, Dunleavy K, Roschewski M, <i> et al.</i>: Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell.</i> 2017; <b>31</b>(6): 833–843.e5. <a target=xrefwindow id=d13902e1260 href="http://www.ncbi.nlm.nih.gov/pubmed/28552327">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1263 href="https://doi.org/10.1016/j.ccell.2017.04.012">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1267 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5571650">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727663539">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d13902e1280 class=n-a></a>Brown JR, Byrd JC, Coutre SE, <i> et al.</i>: Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. <i>Blood.</i> 2014; <b>123</b>(22): 3390–7. <a target=xrefwindow id=d13902e1291 href="http://www.ncbi.nlm.nih.gov/pubmed/24615777">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1294 href="https://doi.org/10.1182/blood-2013-11-535047">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4123414">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d13902e1307 class=n-a></a>O'Brien SM, Lamanna N, Kipps TJ, <i> et al.</i>: A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood.</i> 2015; <b>126</b>(25): 2686–94. <a target=xrefwindow id=d13902e1318 href="http://www.ncbi.nlm.nih.gov/pubmed/26472751">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1321 href="https://doi.org/10.1182/blood-2015-03-630947">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1325 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4732760">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d13902e1334 class=n-a></a>Furman RR, Sharman JP, Coutre SE, <i> et al.</i>: Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2014; <b>370</b>(11): 997–1007. <a target=xrefwindow id=d13902e1345 href="http://www.ncbi.nlm.nih.gov/pubmed/24450857">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1348 href="https://doi.org/10.1056/NEJMoa1315226">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1352 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4161365">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727373020"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1361 class=n-a></a>Jones JA, Robak T, Brown JR, <i> et al.</i>: Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematol.</i> 2017; <b>4</b>(3): e114–e126. <a target=xrefwindow id=d13902e1372 href="http://www.ncbi.nlm.nih.gov/pubmed/28257752">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1375 href="https://doi.org/10.1016/S2352-3026(17)30019-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727373020">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727253578"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1388 class=n-a></a>Zelenetz AD, Barrientos JC, Brown JR, <i> et al.</i>: Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(3): 297–311. <a target=xrefwindow id=d13902e1399 href="http://www.ncbi.nlm.nih.gov/pubmed/28139405">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1402 href="https://doi.org/10.1016/S1470-2045(16)30671-4">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1406 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5589180">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727253578">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726938665"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1420 class=n-a></a>Lafon-Desmurs B, Monsel G, Leblond V, <i> et al.</i>: Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia. <i>Med Mal Infect.</i> 2017; <b>47</b>(4): 293–6. <a target=xrefwindow id=d13902e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/27818019">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1434 href="https://doi.org/10.1016/j.medmal.2016.10.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726938665">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d13902e1447 class=n-a></a>Lampson BL, Kim HT, Davids MS, <i> et al.</i>: Efficacy results of a phase 2 trial evaluating idelalisib plus ofatumumab in patients with previously untreated chronic lymphocytic leukemia, #1734. 59th Annual American Society of Hematology Meeting. 2017.</span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725994198"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1459 class=n-a></a>Roberts AW, Davids MS, Pagel JM, <i> et al.</i>: Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2016; <b>374</b>(4): 311–22. <a target=xrefwindow id=d13902e1470 href="http://www.ncbi.nlm.nih.gov/pubmed/26639348">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1473 href="https://doi.org/10.1056/NEJMoa1513257">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725994198">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726356653"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1486 class=n-a></a>Stilgenbauer S, Eichhorst B, Schetelig J, <i> et al.</i>: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study. <i>Lancet Oncol.</i> 2016; <b>17</b>(6): 768–78. <a target=xrefwindow id=d13902e1497 href="http://www.ncbi.nlm.nih.gov/pubmed/27178240">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1500 href="https://doi.org/10.1016/S1470-2045(16)30019-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726356653">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733445115"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1513 class=n-a></a>Davids MS, Hallek M, Wierda W, <i> et al.</i>: Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clin Cancer Res.</i> 2018; <b>24</b>(18): 4371–9. <a target=xrefwindow id=d13902e1524 href="http://www.ncbi.nlm.nih.gov/pubmed/29895707">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1527 href="https://doi.org/10.1158/1078-0432.CCR-17-3761">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733445115">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734439479"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1540 class=n-a></a>Vaxman I, Sidiqi MH, Gertz M: Venetoclax for the treatment of multiple myeloma. <i>Expert Rev Hematol.</i> 2018; <b>11</b>(12): 915–20. <a target=xrefwindow id=d13902e1548 href="http://www.ncbi.nlm.nih.gov/pubmed/30428277">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1551 href="https://doi.org/10.1080/17474086.2018.1548931">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734439479">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733898432"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1565 class=n-a></a>El-Cheikh J, Moukalled NM, El Darsa H, <i> et al.</i>: Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clin Lymphoma Myeloma Leuk.</i> 2018; <b>18</b>(10): e441–e444. <a target=xrefwindow id=d13902e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/30166258">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1579 href="https://doi.org/10.1016/j.clml.2018.07.289">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733898432">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734297176"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1592 class=n-a></a>DiNardo CD, Pratz K, Pullarkat V, <i> et al.</i>: Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. <i>Blood.</i> 2019; <b>133</b>(1): 7–17. <a target=xrefwindow id=d13902e1603 href="http://www.ncbi.nlm.nih.gov/pubmed/30361262">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1606 href="https://doi.org/10.1182/blood-2018-08-868752">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1610 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6318429">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734297176">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734628348"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1623 class=n-a></a>Uchida A, Isobe Y, Asano J, <i> et al.</i>: Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with <i>MYC</i> and <i>BCL2</i> rearrangements. <i>Haematologica.</i> 2018; <b>104</b>(7): 1417–1421. <a target=xrefwindow id=d13902e1641 href="http://www.ncbi.nlm.nih.gov/pubmed/30523053">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1644 href="https://doi.org/10.3324/haematol.2018.204958">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6601100">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734628348">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734569400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1660 class=n-a></a>Fishman JA, Hogan JI, Maus MV: Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. <i>Clin Infect Dis.</i> 2018. <a target=xrefwindow id=d13902e1665 href="http://www.ncbi.nlm.nih.gov/pubmed/30520987">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1668 href="https://doi.org/10.1093/cid/ciy1025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734569400">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d13902e1681 class=n-a></a>June CH, Sadelain M: Chimeric Antigen Receptor Therapy. <i>N Engl J Med.</i> 2018; <b>379</b>(1): 64–73. <a target=xrefwindow id=d13902e1689 href="http://www.ncbi.nlm.nih.gov/pubmed/29972754">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1692 href="https://doi.org/10.1056/NEJMra1706169">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732586746"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1701 class=n-a></a>Maude SL, Laetsch TW, Buechner J, <i> et al.</i>: Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>N Engl J Med.</i> 2018; <b>378</b>(5): 439–48. <a target=xrefwindow id=d13902e1712 href="http://www.ncbi.nlm.nih.gov/pubmed/29385370">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1715 href="https://doi.org/10.1056/NEJMoa1709866">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1719 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5996391">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732586746">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d13902e1733 class=n-a></a>Maus MV, June CH: Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. <i>Clin Cancer Res.</i> 2016; <b>22</b>(8): 1875–84. <a target=xrefwindow id=d13902e1741 href="http://www.ncbi.nlm.nih.gov/pubmed/27084741">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1744 href="https://doi.org/10.1158/1078-0432.CCR-15-1433">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1747 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4843171">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732586745"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1756 class=n-a></a>Park JH, Rivière I, Gonen M, <i> et al.</i>: Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. <i>N Engl J Med.</i> 2018; <b>378</b>(5): 449–59. <a target=xrefwindow id=d13902e1767 href="http://www.ncbi.nlm.nih.gov/pubmed/29385376">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1770 href="https://doi.org/10.1056/NEJMoa1709919">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732586745">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734540971"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1783 class=n-a></a>Schuster SJ, Bishop MR, Tam CS, <i> et al.</i>: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>N Engl J Med.</i> 2019; <b>380</b>(1): 45–56. <a target=xrefwindow id=d13902e1794 href="http://www.ncbi.nlm.nih.gov/pubmed/30501490">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1797 href="https://doi.org/10.1056/NEJMoa1804980">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734540971">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734570341"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1810 class=n-a></a>Locke FL, Ghobadi A, Jacobson CA, <i> et al.</i>: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncol.</i> 2019; <b>20</b>(1): 31–42. <a target=xrefwindow id=d13902e1821 href="http://www.ncbi.nlm.nih.gov/pubmed/30518502">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1824 href="https://doi.org/10.1016/S1470-2045(18)30864-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734570341">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732756257"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1837 class=n-a></a>Park JH, Romero FA, Taur Y, <i> et al.</i>: Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. <i>Clin Infect Dis.</i> 2018; <b>67</b>(4): 533–40. <a target=xrefwindow id=d13902e1848 href="http://www.ncbi.nlm.nih.gov/pubmed/29481659">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1851 href="https://doi.org/10.1093/cid/ciy152">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1855 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6070095">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732756257">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732006346"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1868 class=n-a></a>Hill JA, Li D, Hay KA, <i> et al.</i>: Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood.</i> 2018; <b>131</b>(1): 121–130. <a target=xrefwindow id=d13902e1879 href="http://www.ncbi.nlm.nih.gov/pubmed/29038338">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1882 href="https://doi.org/10.1182/blood-2017-07-793760">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1886 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5755046">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732006346">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734621503"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1900 class=n-a></a>Darvin P, Toor SM, Sasidharan Nair V, <i> et al.</i>: Immune checkpoint inhibitors: recent progress and potential biomarkers. <i>Exp Mol Med.</i> 2018; <b>50</b>(12): 165. <a target=xrefwindow id=d13902e1911 href="http://www.ncbi.nlm.nih.gov/pubmed/30546008">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1914 href="https://doi.org/10.1038/s12276-018-0191-1">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1918 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6292890">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734621503">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727022418"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1931 class=n-a></a>Hude I, Sasse S, Engert A, <i> et al.</i>: The emerging role of immune checkpoint inhibition in malignant lymphoma. <i>Haematologica.</i> 2017; <b>102</b>(1): 30–42. <a target=xrefwindow id=d13902e1942 href="http://www.ncbi.nlm.nih.gov/pubmed/27884973">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1945 href="https://doi.org/10.3324/haematol.2016.150656">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1949 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5210230">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727022418">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d13902e1962 class=n-a></a>Lulla P, Heslop HE: Checkpoint inhibition and cellular immunotherapy in lymphoma. <i>Hematology Am Soc Hematol Educ Program.</i> 2016; <b>2016</b>(1): 390–6. <a target=xrefwindow id=d13902e1970 href="http://www.ncbi.nlm.nih.gov/pubmed/27913506">PubMed Abstract </a> | <a target=xrefwindow id=d13902e1973 href="https://doi.org/10.1182/asheducation-2016.1.390">Publisher Full Text </a> | <a target=xrefwindow id=d13902e1976 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6142511">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733207503"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e1985 class=n-a></a>Shah GL, Moskowitz CH: Checkpoint inhibition in lymphoma. <i>Clin Adv Hematol Oncol.</i> 2018; <b>16</b>(1): 45–55. <a target=xrefwindow id=d13902e1993 href="http://www.ncbi.nlm.nih.gov/pubmed/29741505">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733207503">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d13902e2006 class=n-a></a>Attanasio J, Wherry EJ: Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. <i>Immunity.</i> 2016; <b>44</b>(5): 1052–68. <a target=xrefwindow id=d13902e2014 href="http://www.ncbi.nlm.nih.gov/pubmed/27192569">PubMed Abstract </a> | <a target=xrefwindow id=d13902e2017 href="https://doi.org/10.1016/j.immuni.2016.04.022">Publisher Full Text </a> | <a target=xrefwindow id=d13902e2020 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4873956">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727133783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e2029 class=n-a></a>Grimaldi D, Pradier O, Hotchkiss RS, <i> et al.</i>: Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. <i>Lancet Infect Dis.</i> 2017; <b>17</b>(1): 18. <a target=xrefwindow id=d13902e2040 href="http://www.ncbi.nlm.nih.gov/pubmed/27998559">PubMed Abstract </a> | <a target=xrefwindow id=d13902e2043 href="https://doi.org/10.1016/S1473-3099(16)30541-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727133783">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732634217"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d13902e2057 class=n-a></a>Daver N, Kontoyiannis DP: Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. <i>Lancet Oncol.</i> 2017; <b>18</b>(12): 1571–3. <a target=xrefwindow id=d13902e2065 href="http://www.ncbi.nlm.nih.gov/pubmed/29208429">PubMed Abstract </a> | <a target=xrefwindow id=d13902e2068 href="https://doi.org/10.1016/S1470-2045(17)30852-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732634217">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 26 Jul 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1202.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1202.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Dipartimento di Ematologia, Oncologia, e Dermatologia, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy<br/> <p> <div class=margin-bottom> Corrado Girmenia <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1202/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 26 Jul 2019, 8:1202 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.17836.1">https://doi.org/10.12688/f1000research.17836.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Girmenia C. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=19501 data-id=17836 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17836.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1202/v1/pdf?article_uuid=d7f2d693-3c39-476d-80ba-44b5a32ae7df" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.17836.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Girmenia C. New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1202 (<a href="https://doi.org/10.12688/f1000research.17836.1" target=_blank>https://doi.org/10.12688/f1000research.17836.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=17836 id=mobile-track-article-signin-17836 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17836?target=/articles/8-1202.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19501 /> <input name=articleId type=hidden value=17836 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>David S. Perlin</strong>, Center for Discovery and Innovation, Hackensack Meridian Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Marcio Nucci</strong>, Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro, Brazil </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Marcio Nucci and Corrado Girmenia have collaborated together on ECIL-6 Guideline articles in the last three years. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Russell E Lewis</strong>, Clinic of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Russell E Lewis and Corrado Girmenia have collaborated together on ECIL-6 Guideline articles in the last three years. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 26 Jul 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1202.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1202.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53540-51679></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53542-51689></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=53543-51690></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1202/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>26 Jul 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>David S. Perlin</strong>, Center for Discovery and Innovation, Hackensack Meridian Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Marcio Nucci</strong>, Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro, Brazil </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Marcio Nucci and Corrado Girmenia have collaborated together on ECIL-6 Guideline articles in the last three years. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Russell E Lewis</strong>, Clinic of Infectious Diseases, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Russell E Lewis and Corrado Girmenia have collaborated together on ECIL-6 Guideline articles in the last three years. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1202.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1202/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "New hematologic populations at risk of invasive...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1202/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1202/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1202/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Girmenia C');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1202/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1202",
            templates : {
                twitter : "New hematologic populations at risk of invasive aspergillosis:.... Girmenia C, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1202/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/17836/19501")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "19501");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "51689": 0,
                           "51690": 0,
                           "51678": 0,
                           "51679": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "01e0129b-35e0-475f-bc97-292d3c0dfd34";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1202.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1202.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1202.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1202.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1202.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>